There are few studies on the impact of NACT on the TME for HER2(+) GC, let alone less research on the changes of immune-infiltrating cells in the TME before and after NACT with Trastuzumab in HER2(+) GC. The gene discussed is ERBB2; the disease is gastric cancer.